跳至主要内容

Active metabolomics: new pathways to uncovering bioactive metabolites

Active metabolomics has become a powerful and disruptive research tool, taking our understanding of bioactive metabolites to a whole new level. This brand-new research method uses high-throughput and high-sensitivity analysis technology to conduct comprehensive qualitative and quantitative measurements of all metabolites in biological systems and analyze their interrelationships to gain a deeper understanding of biological systems.

Bioactive metabolites, including various enzymes, hormones, etc., are indispensable components in life activities. However, precise identification of these metabolites is not easy in the face of complex biological systems. Traditional biochemical techniques often can only study a specific metabolite due to time and cost considerations. On the contrary, active metabolomics breaks this limitation and provides a global perspective, allowing us to observe and analyze all active metabolites in organisms.

Active metabolomics first extracts and analyzes biological samples to generate a large amount of data. Subsequently, through data processing and bioinformatics analysis, various active metabolites were identified and their interrelationships were established. Technologies used in this process include mass spectrometry, nuclear magnetic resonance (NMR), high performance liquid chromatography (HPLC), and gas chromatography (GC).


In addition, data analysis and interpretation have always been an important challenge in active metabolomics. In recent years, many scholars have conducted in-depth research in this field, developed new statistical methods and calculation models, and continuously improved the accuracy and efficiency of data processing.

Active metabolomics provides us with a new perspective that allows us to gain a deeper understanding of the origin, properties, and mechanisms of action of bioactive metabolites. This will have a profound impact on future biological research and provide us with new means and new paths for understanding the mysteries of life.

The MetID team of Medicilon is composed of experienced scientists. We provide fast and reliable in vivo and in vitro MetID and reactive metabolite capture services. We also support new drug screening and domestic and oversees IND filings. Since the establishment of MetID team, Medicilon has successfully completed multiple different types of research projects for clients, including challenging peptide MetID research.

评论

此博客中的热门博文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...

Medicilon assisted Hangzhou DAC Biotech in approval of clinical study of ADC drug DAC-002

  On July 20, 2020, DAC Biotech’s new   ADC drug development , TROP2-ADC—DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor. Medicilon completed   preclinical pharmacokinetic  and toxicological studies in this project, accelerating the development process. DAC-002 is an ADC anti-Trop2 monoclonal antibody conjugated by an intelligent ligand against Tubulysin B analogue. It is used to treat Trop2 triple negative breast cancer, small cell lung cancer, non-small cell lung cancer and pancreatic cancer.Trop2 can promote the proliferation, invasion, metastasis and diffusion of tumor cells, and its high expression is closely related to the shortening of survival time and poor prognosis of tumor patients. Therefore, it is of great significance to study anti-tumor drugs targeted by Trop2. Reference: Medicilon Assists - The first China-made targeting folic acid receptor FRα ADC injection BAT8006 was approved for clinical use Medicilon As...

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...